End-of-day quote
Korea S.E.
23:00:00 23/05/2024 BST
|
5-day change
|
1st Jan Change
|
4,730
KRW
|
+0.64%
|
|
+3.61%
|
-21.56%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,131,552
|
1,033,808
|
866,567
|
1,243,785
|
716,461
|
619,837
|
Enterprise Value (EV)
1 |
5,021,763
|
985,877
|
860,153
|
1,139,382
|
656,589
|
580,236
|
P/E ratio
|
-90.5
x
|
-9.09
x
|
-18.1
x
|
-63.9
x
|
-29.1
x
|
-30.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
665
x
|
114
x
|
519
x
|
4,890
x
|
143
x
|
157
x
|
EV / Revenue
|
651
x
|
109
x
|
515
x
|
4,479
x
|
131
x
|
147
x
|
EV / EBITDA
|
-90.1
x
|
-17.9
x
|
-26.1
x
|
-59.2
x
|
-28.2
x
|
-28.5
x
|
EV / FCF
|
-195
x
|
-26.1
x
|
-35.8
x
|
-224
x
|
-18.1
x
|
-44.1
x
|
FCF Yield
|
-0.51%
|
-3.83%
|
-2.79%
|
-0.45%
|
-5.53%
|
-2.27%
|
Price to Book
|
31.1
x
|
16.9
x
|
37.8
x
|
11.5
x
|
9.08
x
|
10.8
x
|
Nbr of stocks (in thousands)
|
69,817
|
71,052
|
71,617
|
102,792
|
102,792
|
102,792
|
Reference price
2 |
73,500
|
14,550
|
12,100
|
12,100
|
6,970
|
6,030
|
Announcement Date
|
19/03/19
|
30/03/20
|
22/03/21
|
22/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,712
|
9,069
|
1,670
|
254.4
|
5,013
|
3,940
|
EBITDA
1 |
-55,740
|
-55,149
|
-32,933
|
-19,239
|
-23,248
|
-20,326
|
EBIT
1 |
-59,279
|
-58,493
|
-34,661
|
-20,378
|
-24,447
|
-21,472
|
Operating Margin
|
-768.66%
|
-645%
|
-2,075.86%
|
-8,011.5%
|
-487.63%
|
-545.04%
|
Earnings before Tax (EBT)
1 |
-55,433
|
-113,196
|
-47,825
|
-22,124
|
-23,901
|
-20,181
|
Net income
1 |
-56,236
|
-113,200
|
-47,825
|
-16,006
|
-24,593
|
-20,369
|
Net margin
|
-729.2%
|
-1,248.27%
|
-2,864.25%
|
-6,292.62%
|
-490.55%
|
-517.04%
|
EPS
2 |
-812.0
|
-1,600
|
-668.0
|
-189.3
|
-239.3
|
-198.2
|
Free Cash Flow
1 |
-25,788
|
-37,751
|
-23,999
|
-5,084
|
-36,328
|
-13,156
|
FCF margin
|
-334.39%
|
-416.29%
|
-1,437.32%
|
-1,998.65%
|
-724.62%
|
-333.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
30/03/20
|
22/03/21
|
22/03/22
|
23/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
109,789
|
47,932
|
6,414
|
104,403
|
59,872
|
39,600
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-25,788
|
-37,751
|
-23,999
|
-5,084
|
-36,328
|
-13,156
|
ROE (net income / shareholders' equity)
|
-30.6%
|
-100%
|
-114%
|
-24.5%
|
-26.3%
|
-29.9%
|
ROA (Net income/ Total Assets)
|
-17.3%
|
-27.8%
|
-37%
|
-14%
|
-12.8%
|
-14.9%
|
Assets
1 |
324,937
|
407,090
|
129,334
|
114,519
|
191,762
|
136,726
|
Book Value Per Share
2 |
2,365
|
858.0
|
320.0
|
1,051
|
768.0
|
558.0
|
Cash Flow per Share
2 |
342.0
|
113.0
|
62.80
|
477.0
|
123.0
|
229.0
|
Capex
1 |
283
|
792
|
73.6
|
64.6
|
292
|
351
|
Capex / Sales
|
3.67%
|
8.73%
|
4.41%
|
25.38%
|
5.82%
|
8.92%
|
Announcement Date
|
19/03/19
|
30/03/20
|
22/03/21
|
22/03/22
|
23/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -21.56% | 354M | | +12.11% | 116B | | +12.68% | 106B | | -9.78% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -14.75% | 16.33B | | +6.20% | 14.14B | | +29.46% | 12.02B |
Bio Therapeutic Drugs
|